GB stock · Healthcare sector · Drug Manufacturers—General
Company Logo

GSK plc

GSKNYSE

34.76

USD
+0.04
(+0.12%)
Market Closed
12.99P/E
9Forward P/E
0.62P/E to S&P500
71.171BMarket CAP
1.66%Div Yield

GSK plc

NYSE:GSK

RECENT
PRICE

34.76

P/E
RATIO

12.99

(PEG:0.05)

P/E RATIO
RELATIVE
TO S&P

0.62

DIV
YLD

4.41%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

- - Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 06/23:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

Fiscal year

10.29

2.39

1.23

1.15

10.29

2.36

1.82

1.27

11.64

2.25

2.45

1.44

13.99

2.73

2.94

1.52

13.94

0.80

2.54

1.57

13.62

2.62

2.45

1.69

13.45

2.32

1.45

1.94

13.72

2.81

2.86

1.90

11.96

1.43

1.78

2.00

12.38

4.36

0.35

2.00

14.35

0.47

2.13

2.49

15.45

0.78

2.41

2.00

15.68

1.84

3.37

2.00

17.06

2.35

2.96

2.00

17.13

2.89

3.12

2.00

17.05

2.19

2.51

2.00

14.57

7.43

2.56

1.72

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.70

4.16

0.97

4.35

0.99

3.79

0.92

4.93

0.80

4.36

0.66

3.99

0.77

2.96

0.88

3.62

0.91

2.22

0.98

2.65

1.21

0.58

1.13

(0.03)

0.91

2.22

1.09

5.76

1.12

7.33

1.46

7.52

1.12

5.26

CAPEX per share

Book Value per share

2,257

2,210

2,092

2,028

2,036

2,011

1,965

1,932

1,923

1,932

1,944

1,954

1,966

1,979

1,990

2,001

2,013

Comm.Shares outs.(m)

- -

- -

- -

28.3

1.63

1.89%

23.9

1.11

2.67%

16.6

0.23

3.36%

59.3

2.86

3.31%

19.8

1.22

3.26%

24.3

1.63

3.44%

22.1

1.30

3.06%

43.9

2.42

3.17%

12.4

0.62

3.71%

110.1

4.96

4.83%

63.8

2.71

3.99%

26.7

1.07

4.07%

22.1

0.91

3.85%

17.3

0.46

3.99%

22.4

0.74

4.08%

6.1

0.29

3.80%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/12/22 | Q4)

Total liabilities
$50,050 m.

Total assets
$60,146 m.

Long-term debt
$17,035 m.

Cash and equiv.
$3,723 m.

Goodwill $7,046 m.

Retained earnings $4,363 m.

Common stock 2,017 m. shares

Market Capitalisation
$68,631 m. (as of 11/6/23)

27,387

28.5%

26,431

28.0%

26,505

26.5%

23,006

15.6%

23,923

43.1%

27,889

9.3%

30,186

13.5%

30,821

17.8%

33,754

20.6%

34,099

22.8%

34,114

18.2%

29,324

21.9%

Revenue (m)

Operating margin

1,423

5,261

1,445

4,565

1,414

5,436

1,484

2,756

1,630

8,422

1,774

912

1,922

1,532

1,856

3,623

2,334

4,645

2,351

5,749

2,377

4,385

2,298

14,956

Depreciation (m)

Net profit (m)

29.1%

19.2%

29.1%

17.3%

15.3%

20.5%

4.6%

12.0%

20.5%

35.2%

45.2%

3.3%

38.5%

5.1%

15.7%

11.8%

15.3%

13.8%

8.3%

16.9%

6.4%

12.9%

12.6%

51.0%

Income tax rate

Net profit margin

1,157

12,203

8,032

(123)

14,671

5,810

1,550

15,456

6,997

1,383

15,841

4,263

3,170

15,324

5,114

(2,290)

14,661

1,124

(10,662)

14,264

(68)

(5,564)

20,271

4,360

(4,559)

23,590

11,405

(1,901)

23,425

14,587

(4,996)

20,572

15,055

(2,041)

17,035

10,598

Working capital (m)

Long-term debt (m)

Equity (m)

23.3%

20.6%

65.5%

19.3%

17.9%

78.6%

22.1%

17.4%

77.7%

12.9%

9.0%

64.6%

24.8%

22.8%

164.7%

3.8%

4.5%

81.1%

8.5%

6.9%

(2,252.9)%

12.0%

8.8%

83.1%

11.3%

8.9%

40.7%

12.7%

9.7%

39.4%

10.5%

7.6%

29.1%

38.2%

27.3%

141.1%

ROIC

Return on capital

Return on equity

Working Capital

2020

2021

2022

Cash assets

6,170

4,152

3,801

Receivables

- -

- -

- -

Inventory

5,996

5,783

5,146

Other

8,081

8,756

7,746

Current assets

20,247

18,674

20,769

Acc. Payable

4,357

4,535

16,263

Debt due

3,725

3,601

3,952

Other

14,066

15,534

2,595

Current liab.

22,148

23,670

22,810

(73.0)%

60.9%

37.6%

108.5%

19.6%

207.7%

34.6%

84.1%

(35.7)%

117.1%

53.7%

583.8%

(356.7)%

116.6%

(80.1)%

83.0%

2.9%

58.2%

25.0%

66.6%

37.7%

63.7%

21.5%

79.2%

Plowback ratio

Div.&Repurch. to FCF

GSK plc (GB) started trading on Invalid Date (cik: 0001131399), operates in the Healthcare sector (Drug Manufacturers—General industry), has 90,096 full-time employees, and is led by Ms. Emma Natasha Walmsley. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

-0.86%

1.58%

Cash flow

-5.57%

48.23%

Earnings

67.33%

60.10%

Dividends

-2.87%

0.00%

Book value

40.77%

-727.98%

Insider trading

Type

Shares

Date

Nothing found

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

9,090

7,624

8,646

8,739

34,099

2021

7,418

8,092

9,077

9,527

34,114

2022

9,780

6,929

7,829

7,376

31,914

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.79

1.14

0.63

0.34

2.89

2021

0.54

0.70

0.58

0.37

2.19

2022

0.90

0.42

5.14

0.74

7.20

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

0.47

0.57

0.48

0.48

2.00

2021

0.47

0.58

0.48

0.48

2.00

2022

0.47

0.57

0.35

0.32

1.72

10/31/2022

Drugmakers Fight Over Lucrative Pneumonia Vaccines

The Wall Street Journal - Read more...

01/19/2022

Unilever Walks Away From Glaxo Consumer-Healthcare Deal

The Wall Street Journal - Read more...

01/15/2022

Unilever Makes Approach for Glaxo’s Consumer-Healthcare Business

The Wall Street Journal - Read more...

12/07/2021

Tesla, Intel, Bitcoin: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/02/2021

Vir Biotechnology, Digital World Acquisition, Apple: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

05/17/2021

Sanofi-GSK Covid-19 Vaccine Set for Large-Scale Trials After Positive Results

The Wall Street Journal - Read more...